Zenas BioPharma is a company committed to enabling patients with autoimmune diseases to reimagine their lives through the development of immunology-based therapies. The company is advancing immunology programs for multiple autoimmune diseases, with a focus on Obexelimab, a bifunctional monoclonal antibody that suppresses B cell activity, a contributor to many autoimmune diseases. Zenas BioPharma emphasizes the importance of addressing unmet medical needs and is progressing Obexelimab through clinical trials. With a dedicated team, Zenas BioPharma is poised to lead in the development and commercialization of transformative therapies for autoimmune diseases.